Maya Chopra

Has grant

Director of Translational Genomic Medicine

Boston Children's Hospital
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome

Open Date: 2021-01-01

Close Date:

Articles (5)

Year:

2026

Boston Children’s Hospital has established a genomic sequencing and analysis research initiative to improve clinical care for pediatric rare disease patients. Through the Children’s Rare Disease Collaborative (CRDC), the hospital offers CLIA-grade exome and genome sequencing, along with other sequencing types, to patients enrolled in specialized rare disease research studies. The data, consented for broad research use, are harmonized and analyzed with CRDC-supported variant interpretation tools. Since its launch, 66 investigators representing 26 divisions and 45 phenotype-based cohorts have joined the CRDC. These studies enrolled 4653 families, with 35% of analyzed cases having a finding either confirmed or under further investigation. This accessible and harmonized genomics platform also supports additional institutional data collections, research and clinical, and now encompasses 13,800+ patients and their families. This has fostered new research projects and collaborations, increased genetic diagnoses and accelerated innovative research via integration of genomics research with clinical care.

Year:

2024

Year:

2024

Pathogenic ASH1L variants have been reported in probands with broad phenotypic presentations, including intellectual disability, autism spectrum disorder, attention deficit hyperactivity disorder, seizures, congenital anomalies, and other skeletal, muscular, and sleep differences. Here, we review previously published individuals with pathogenic ASH1L variants and report three further probands with novel ASH1L variants and previously unreported phenotypic features, including mixed receptive language disorder and gait disturbances. These novel data from the Brain Gene Registry, an accessible repository of clinically derived genotypic and phenotypic data, have allowed for the expansion of the phenotypic and genotypic spectrum of this condition.

Year:

2024

Of the around 7,000 known rare diseases worldwide, disease-modifying treatments are available for fewer than 5%, leaving millions of individuals without specialized therapeutic strategies. In recent years, antisense oligonucleotides (ASOs) have shown promise as individualized genetic interventions for rare genetic diseases. However, there is currently no consensus on which disease-causing DNA variants are suitable candidates for this type of genetic therapy. The Patient Identification Working Group of the N=1 Collaborative (N1C), alongside an international group of volunteer assessors, has developed and piloted consensus guidelines for assessing the eligibility of pathogenic variants towards ASO treatments. We herein present the N1C VARIANT ( V ariant A ssessments towa r ds El i gibility for An tisense Oligonucleotide T reatment) guidelines, including the guiding scientific principles and our approach to consensus building. Pathogenic, disease-causing variants can be assessed for the three currently best-established ASO treatment approaches: splice correction, exon skipping, and downregulation of RNA transcripts. A genetic variant is classified as either “eligible”, “likely eligible”, “unlikely eligible”, or “not eligible” in relation to the different approaches, or “unable to assess”. We also review key considerations for assessment for upregulation of transcripts from the wildtype allele, an emerging ASO therapeutic strategy. We provide additional tools and training material to enable clinicians and researchers to use these guidelines for their eligibility assessments. With this initial edition of our N1C VARIANT guidelines, we provide the rare genetic disease community with guidance on how to identify suitable candidates for variant-specific ASO-based therapies and the possibility of integrating such assessments into routine clinical practice.

Year:

2024

Collaborators (13)

Gabriele Siegel

University of Zurich

SWITZERLAND
View details

Annemieke Aartsma-Rus

Professor of Translational Genetics

Leiden University Medical Center

NETHERLANDS
View details

Scott Pomeroy

Bronson Crothers Distinguished Professor of Neurology

Harvard University

UNITED STATES
View details

Mina Ryten

University College London

UNITED KINGDOM
View details

Timothy Yu

Associate Member

Broad Institute

UNITED STATES
View details

Alice Davidson

Professor of Molecular Genetics

University College London

UNITED KINGDOM
View details

Anne Gregor

Senior Researcher

University Hospital of Bern

SWITZERLAND
View details

Matthis Synofzik

Professor

Hertie Institute for clinical brain research

GERMANY
View details

Nancy Andrews

Executive Vice President & Chief Scientific Officer

Boston Children's Hospital

UNITED STATES
View details

Catherine Brownstein

Assistant Professor

Boston Children's Hospital

UNITED STATES
View details

Gregory Costain

Hospital for Sick Children

CANADA
View details

Stephan Sanders

Professor of Paediatric Neurogenetics

University of Oxford

UNITED KINGDOM
View details

Hormos Salimi Dafsari

Max Planck Institute for Biology of Ageing

GERMANY
View details